Day One Biopharmaceuticals
DAWN
DAWN
130 hedge funds and large institutions have $952M invested in Day One Biopharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 56 increasing their positions, 35 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
6% less funds holding
Funds holding: 139 → 130 (-9)
17.95% less ownership
Funds ownership: 107.11% → 89.17% (-18%)
38% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 21
Holders
130
Holding in Top 10
2
Calls
$813K
Puts
$775K
Top Buyers
| 1 | +$13.8M | |
| 2 | +$13.2M | |
| 3 | +$5.07M | |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.51M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
+$4.34M |
Top Sellers
| 1 | -$18.8M | |
| 2 | -$17.3M | |
| 3 | -$9.39M | |
| 4 |
Goldman Sachs
New York
|
-$9.16M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$7.76M |